Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Debled

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Diagnostic and Interventional Imaging|March 17, 2012
Radiological features of triple-negative breast cancers (73 cases)M Boisserie-Lacroix, G Mac Grogan, M Debled, et al.
British Journal of Cancer|December 17, 2003
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trialA Ravaud, N Trufflandier, J M Ferrière, et al.
Breast Cancer Research and Treatment|November 21, 2008
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyC Falandry, M Debled, T Bachelot, et al.
Breast (Edinburgh, Scotland)|September 22, 2015
Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective studyD Chocteau-Bouju, C Chakiba, L Mignot, et al.
Diagnostic and Interventional Imaging|December 4, 2014
Hepar lobatum carcinomatosum associated with liver metastases from breast cancer: report of five casesN Alberti, D Bechade, F Dupuis, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 14, 2011
Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-upA Avril, G Le Bouëdec, G Lorimier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective seriesM J Rodrigues, J Peron, J-S Frénel, et al.
Gynecologie, Obstetrique & Fertilite|April 22, 2008
[Male breast cancer: a review of 52 cases collected at the Institute Bergonié (Bordeaux, France) from 1980 to 2004]C Tunon de Lara, G Goudy, G Macgrogan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2012
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancerH Bonnefoi, K Zaman, M Debled, et al.
ESMO Open|June 27, 2022
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapyC Blaye, É Darbo, M Debled, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Diagnostic and Interventional Imaging|March 17, 2012
Radiological features of triple-negative breast cancers (73 cases)M Boisserie-Lacroix, G Mac Grogan, M Debled, et al.
British Journal of Cancer|December 17, 2003
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trialA Ravaud, N Trufflandier, J M Ferrière, et al.
Breast Cancer Research and Treatment|November 21, 2008
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyC Falandry, M Debled, T Bachelot, et al.
Breast (Edinburgh, Scotland)|September 22, 2015
Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective studyD Chocteau-Bouju, C Chakiba, L Mignot, et al.
Diagnostic and Interventional Imaging|December 4, 2014
Hepar lobatum carcinomatosum associated with liver metastases from breast cancer: report of five casesN Alberti, D Bechade, F Dupuis, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 14, 2011
Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-upA Avril, G Le Bouëdec, G Lorimier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective seriesM J Rodrigues, J Peron, J-S Frénel, et al.
Gynecologie, Obstetrique & Fertilite|April 22, 2008
[Male breast cancer: a review of 52 cases collected at the Institute Bergonié (Bordeaux, France) from 1980 to 2004]C Tunon de Lara, G Goudy, G Macgrogan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2012
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancerH Bonnefoi, K Zaman, M Debled, et al.
ESMO Open|June 27, 2022
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapyC Blaye, É Darbo, M Debled, et al.
Pageof 5